Supporting the industry during the COVID-19 pandemic
Undoubtedly, you have received a multitude of emails regarding COVID-19. While no one could predict the disruption COVID-19 would have on our lives, Absorption Systems has long instituted policies within the company for redundancy and mitigation strategies. As a CRO working with various biological materials, our standard policies already include our technical team wearing proper PPE (gowns, lab coats, gloves, head, shoe covers and masks) to ensure safe working conditions. Additionally, we are doing our due diligence to minimize exposure by deep cleaning all work surfaces, limiting large non-essential meetings, and non-essential on-site visitors.
We have reached out to all of our vendors to determine if the supply of any reagents we purchase could be at risk. We are self-isolating staff who have the ability to work from home and being vigilant about any employee exhibiting symptoms to ensure they do not come to work.
So you are aware, at this time we have no health concerns with any of our staff and do not anticipate any impact on the scheduling, conduct, and execution of your studies. At this time, all studies which have been initiated are progressing and we also have the capacity for additional studies. If in the worst case scenario after scheduling your study there is a need to postpone for reasons not in our control, rest assured we will work quickly to identify new dates. The communication channel will remain the same and your primary contact will provide immediate updates and work to find a quick resolution.
If you require any further details regarding your in-progress or upcoming projects, please connect with your primary contact or email contact@absorption.com and we are happy to provide all the necessary information. We also now have a chat functionality accessed via an orange oval on the bottom right corner of every web page.
Please do not hesitate to reach out if there’s anything we can do to help with your continuity of operations.
To the research and commercial communities developing diagnostic testing and therapeutics for COVID-19
Absorption Systems possesses several capabilities that can be utilized for supporting COVID-19 testing and vaccine development. These include development, qualification, and validation for ELISA formats for detecting and quantifying biologics in various matrices, detection of viral shedding and copy number using RT-PCR as well as FACS and high content imaging capabilities for looking at cellular markers associated with the viral infection. All these capabilities can be conducted in compliance with GLP and cGMP guidelines. We also offer services in support of anti-viral drug development, including animal pharmacokinetic studies. We have the QA and IT support infrastructure to conduct these studies in compliance with current FDA and EMA standards.
We stand ready to help.
